suvizumab

{{Short description|Monoclonal antibody}}

{{Drugbox

| Verifiedfields = changed

| verifiedrevid = 470475254

| type = mab

| image =

| alt =

| mab_type = mab

| source = zu

| target = HIV-1

| tradename =

| Drugs.com =

| MedlinePlus =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category=

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = none

| CAS_number_Ref = {{cascite|changed|??}}

| CAS_number = 914257-21-9

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = 4AJ2TI6DPI

| ATC_prefix = none

| ATC_suffix =

| PubChem =

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| chemical_formula =

| molecular_weight =

}}

Suvizumab is an experimental antiviral drug and immunomodulator. It is a monoclonal antibody that binds to HIV-1.{{cite journal |title = Proposed List number 102 of International Nonproprietary Names|journal = WHO Drug Information|year = 2009|url =https://www.who.int/entity/medicines/publications/druginformation/innlists/PL_102.pdf|publisher = World Health Organization|location = Geneva|issn = 1010-9609|page = 344|volume = 23|issue = 4}}